systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»systhiper-156Research ArticleСТАТЬИARTICLESДинамика скорости клубочковой фильтрации - самостоятельная мишень антигипертензивной терапии: возможности эпросартанаФоминВ. В.noemail@neicon.ruКафедра терапии и профболезней ММА им. И.М.СеченоваRussian Federation200823122022537175Copyright © Фомин В.В., 20222022Фомин В.В.Фомин В.В.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/156ReferencesESH-ESC Guidelines Committee. 2007 guidelines for the management of arterial hypertension. J Hypertens 2007; 25: 1105-87.ESH-ESC Guidelines Committee. 2007 guidelines for the management of arterial hypertension. J Hypertens 2007; 25: 1105-87.Diehm C, Lange S, Darius H et al. Association of low ankle brachial index with high mortality in primary care. Eur Heart J 2006; 27 (14): 1743-9.Diehm C, Lange S, Darius H et al. Association of low ankle brachial index with high mortality in primary care. Eur Heart J 2006; 27 (14): 1743-9.Бойцов С.А. Изучение патогенеза гипертонической болезни продолжается. Тер. арх. 2006; 9: 5-12.Бойцов С.А. Изучение патогенеза гипертонической болезни продолжается. Тер. арх. 2006; 9: 5-12.Nichols WW. Clinical measurement of arterial stiffness obtained from noninvasive pressure waveforms. Am J Hypertens 2005; 18: 3S-10SNichols WW. Clinical measurement of arterial stiffness obtained from noninvasive pressure waveforms. Am J Hypertens 2005; 18: 3S-10SМухин Н.А. Снижение скорости клубочковой фильтрации - общепопуляционный маркер неблагоприятного прогноза. Тер. арх. 2007; 6: 5-10.Мухин Н.А. Снижение скорости клубочковой фильтрации - общепопуляционный маркер неблагоприятного прогноза. Тер. арх. 2007; 6: 5-10.Земченков А.Ю., Томилина Н.А. «К/ДОКИ» обращается к истокам хронической почечной недостаточности (О новом разделе Рекомендаций K/DOQI по диагностике, классификации и оценке тяжести хронических заболеваний почек). Нефрол. и диализ 2004; 6(3): 204-20.Земченков А.Ю., Томилина Н.А. «К/ДОКИ» обращается к истокам хронической почечной недостаточности (О новом разделе Рекомендаций K/DOQI по диагностике, классификации и оценке тяжести хронических заболеваний почек). Нефрол. и диализ 2004; 6(3): 204-20.El Nahas AM, Bello AK. Chronic kidney disease: the global challenge. Lancet 2005; 365: 331-40.El Nahas AM, Bello AK. Chronic kidney disease: the global challenge. Lancet 2005; 365: 331-40.Clase CM, Garg AX, Kiberd BA. Prevalence of low glomerular filtration rate in nondiabetic Americans: Third National Health and Nutrition Examination Survey (NHANES III). J Am Soc Nephrol 2002; 13 (5): 1338-49.Clase CM, Garg AX, Kiberd BA. Prevalence of low glomerular filtration rate in nondiabetic Americans: Third National Health and Nutrition Examination Survey (NHANES III). J Am Soc Nephrol 2002; 13 (5): 1338-49.Redon J, Cea-Calvo L, Lozano JV et al. Kidney function and cardiovascular disease in the hypertensive population: the ERIC-HTA study. J Hypertens 2006; 24 (4): 663-9.Redon J, Cea-Calvo L, Lozano JV et al. Kidney function and cardiovascular disease in the hypertensive population: the ERIC-HTA study. J Hypertens 2006; 24 (4): 663-9.Bibbins-Domingo K, Chertow GM, Fried LF et al. Renal function and heart failure risk in older black and white individuals: the Health, Aging, and Body Composition Study. Arch Intern Med 2006; 166 (13): 1396-402.Bibbins-Domingo K, Chertow GM, Fried LF et al. Renal function and heart failure risk in older black and white individuals: the Health, Aging, and Body Composition Study. Arch Intern Med 2006; 166 (13): 1396-402.Lindholm L, Ibsen H, Dahlof B et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertenstion study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004-10.Lindholm L, Ibsen H, Dahlof B et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertenstion study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004-10.Brown B, Hall A. Renin-angiotensin system: the weight of evidence. Am J Hypertens 2005; 18: 127S-133S.Brown B, Hall A. Renin-angiotensin system: the weight of evidence. Am J Hypertens 2005; 18: 127S-133S.Brenner B, Cooper M, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345 (12): 861-9.Brenner B, Cooper M, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345 (12): 861-9.Lewis E, Hunsicker L, Clarke W et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in nephropathy due to type 2 diabetes. N Engl J Med 2001; 345 (12): 851-60.Lewis E, Hunsicker L, Clarke W et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in nephropathy due to type 2 diabetes. N Engl J Med 2001; 345 (12): 851-60.Schupp M, Pharm B, Janke J et al. Angiotensin type 1 receptor blockers induce peroxisome proliferators-activated receptor-g activity. Circulation 2004; 109: 2054-7.Schupp M, Pharm B, Janke J et al. Angiotensin type 1 receptor blockers induce peroxisome proliferators-activated receptor-g activity. Circulation 2004; 109: 2054-7.Ernsberger P, Koletsky RJ. Metabolic actions of angiotensin receptor antagonists: PPAR-gamma agonist actions or a class effect? Curr Opin Pharmacol 2007; 7 (2): 140-5.Ernsberger P, Koletsky RJ. Metabolic actions of angiotensin receptor antagonists: PPAR-gamma agonist actions or a class effect? Curr Opin Pharmacol 2007; 7 (2): 140-5.Мычка В.Б., Мамырбаева К.М., Масенко В.П. и др. Возможности антигипертензивной терапии ирбесартаном в коррекции инсулинорезистентности и нарушений мозгового кровотока у больных с метаболическим синдромом. Сonsilium Medicum 2006; 8 (11): 25-30.Мычка В.Б., Мамырбаева К.М., Масенко В.П. и др. Возможности антигипертензивной терапии ирбесартаном в коррекции инсулинорезистентности и нарушений мозгового кровотока у больных с метаболическим синдромом. Сonsilium Medicum 2006; 8 (11): 25-30.Kintscher U, Bramlage P, Paar WD et al. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients. Cardiovasc. Diabetol 2007; 6: 12-7.Kintscher U, Bramlage P, Paar WD et al. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients. Cardiovasc. Diabetol 2007; 6: 12-7.Ram CV. Angiotensin blockade with eprosartan: vascular and functional implications. Curr Med Res Opin 2007; 23 (Suppl. 5): S5-S11.Ram CV. Angiotensin blockade with eprosartan: vascular and functional implications. Curr Med Res Opin 2007; 23 (Suppl. 5): S5-S11.Balt JC, Mathy MJ, Nap A et al. Prejunctional and postjunctional inhibitory actions of eprosartan and candesartan in the isolated rabbit mesenteric artery. J Cardiovasc Pharmacol 2002; 40 (1): 50-7.Balt JC, Mathy MJ, Nap A et al. Prejunctional and postjunctional inhibitory actions of eprosartan and candesartan in the isolated rabbit mesenteric artery. J Cardiovasc Pharmacol 2002; 40 (1): 50-7.Ohlstein EH, Brooks DP, Feuerstein GZ, Ruffolo RRJr. Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade. Pharmacology 1997; 55 (5): 244-51.Ohlstein EH, Brooks DP, Feuerstein GZ, Ruffolo RRJr. Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade. Pharmacology 1997; 55 (5): 244-51.Vase H, Lauridsen TG, Bech JN et al. Eprosartan modulates the reflex activation of the sympathetic nervous system in sodium restricted healthy humans. Br J Clin Pharmacol 2008; 65 (6): 822-32.Vase H, Lauridsen TG, Bech JN et al. Eprosartan modulates the reflex activation of the sympathetic nervous system in sodium restricted healthy humans. Br J Clin Pharmacol 2008; 65 (6): 822-32.Jooles JA, Koomans HA. Causes and consequences of increased sympathetic activity in renal disease. Hypertension 2004; 43: 699-706.Jooles JA, Koomans HA. Causes and consequences of increased sympathetic activity in renal disease. Hypertension 2004; 43: 699-706.Rump LC, Amann K, Orth S, Ritz E. Sympathetic overactivity in renal disease: a window to understand progression and cardiovascular complications of uremia. Nephrol Dial Transplant 2000; 15: 1735-48.Rump LC, Amann K, Orth S, Ritz E. Sympathetic overactivity in renal disease: a window to understand progression and cardiovascular complications of uremia. Nephrol Dial Transplant 2000; 15: 1735-48.Neumann J, Ligtenberg G, Klein IH et al. Sympathetic hyperactivity in hypertensive chronic kidney disease patients is reduced during standard treatment. Hypertension 2007; 49 (3): 506-10.Neumann J, Ligtenberg G, Klein IH et al. Sympathetic hyperactivity in hypertensive chronic kidney disease patients is reduced during standard treatment. Hypertension 2007; 49 (3): 506-10.Price DA, De'Oliveira JM, Fisher ND, Hollenberg NK. Renal hemodynamic response to an angiotensin II antagonist, eprosartan, in healthy men. Hypertension 1997; 30 (2 Pt. 1): 240-6.Price DA, De'Oliveira JM, Fisher ND, Hollenberg NK. Renal hemodynamic response to an angiotensin II antagonist, eprosartan, in healthy men. Hypertension 1997; 30 (2 Pt. 1): 240-6.Сагинова Е.А., Федорова Е.А., Фомин В.В. и др. Формирование поражения почек у больных ожирением. Тер. арх. 2005; 5: 36-41.Сагинова Е.А., Федорова Е.А., Фомин В.В. и др. Формирование поражения почек у больных ожирением. Тер. арх. 2005; 5: 36-41.Frank H, Schobel HP, Vitkowsky J et al. Effects of angiotensin II receptor antagonism on the renal hemodynamic response to cardiovascular stress. Kidney Int 2003; 63 (2): 617-23.Frank H, Schobel HP, Vitkowsky J et al. Effects of angiotensin II receptor antagonism on the renal hemodynamic response to cardiovascular stress. Kidney Int 2003; 63 (2): 617-23.Ilson BE, Boike SC, Martin DE et al. A dose-response study to assess the renal hemodynamic, vascular, and hormonal effects of eprosartan, an angiotensin II AT1-receptor antagonist, in sodium-replete healthy men. Clin Pharmacol Ther 1998; 63 (4): 471-81.Ilson BE, Boike SC, Martin DE et al. A dose-response study to assess the renal hemodynamic, vascular, and hormonal effects of eprosartan, an angiotensin II AT1-receptor antagonist, in sodium-replete healthy men. Clin Pharmacol Ther 1998; 63 (4): 471-81.Моисеев С.В., Фомин В.В. Нефрологические аспекты хронической сердечной недостаточности. Тер. арх. 2003; 6: 72-6.Моисеев С.В., Фомин В.В. Нефрологические аспекты хронической сердечной недостаточности. Тер. арх. 2003; 6: 72-6.Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992; 20: 248-54.Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992; 20: 248-54.Brodsky S, Gurbanov K, Abassi Z et al. Effects of eprosartan on renal function and cardiac hypertrophy in rats with experimental heart failure. Hypertension 1998; 32: 746-52.Brodsky S, Gurbanov K, Abassi Z et al. Effects of eprosartan on renal function and cardiac hypertrophy in rats with experimental heart failure. Hypertension 1998; 32: 746-52.
The authors declare that there are no conflicts of interest present.